Press releases

12 June, 2023

Abliva presents scientific data at international conference on mitochondrial medicine

Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage company developing drugs for the treatment of rare and severe primary mitochondrial disease, today announced that the company will present scientif ...

4 May, 2023

Regulatory

Amendment of the Nomination Committee’s proposal for Abliva’s Annual General Meeting in 2023

The notice for Abliva’s Annual General Meeting (AGM) 2023 was announced in a press release on April 4th, 2023. The Nominating Committee’s proposal for the election of Board members was [&h ...

17 April, 2023

Abliva’s Drug Candidate NV354 Granted Orphan Drug Designation for the Treatment of Mitochondrial Disease

Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage company developing medicines for the treatment of rare and severe primary mitochondrial diseases, today announced that the drug candidate NV354 has ...

13 February, 2023

Regulatory

Abliva Nomination Committee to propose Edwin Moses as a new Board member and incoming Chair of the Board of Directors at upcoming General Meetings

The Nomination Committee of Abliva AB proposes that Dr. Edwin Moses be elected as a new Board member of the Company through a shareholder vote at the EGM on March 8, 2023. Dr. Moses, who has over 30 y ...

9 February, 2023

Abliva Announces Issuance of a New U.S. Patent for Therapeutic Compound NV354

Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biotech company developing medicines for the treatment of rare and severe mitochondrial diseases, today announced the granting of a composition of ...

6 December, 2022

Abliva initiates the global FALCON study with lead candidate KL1333

Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biotech company developing medicines for the treatment of rare and severe mitochondrial diseases, today announced the start of the company’s global ...

16 September, 2022

Abliva to participate in World Mitochondrial Disease Week 2022

Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biotech company developing medicines for the treatment of rare and severe primary mitochondrial diseases, today announces that the company will par ...

19 May, 2022

Regulatory

Abliva

Press releases

Abliva presents scientific data at international conference on mitochondrial medicine

Amendment of the Nomination Committee’s proposal for Abliva’s Annual General Meeting in 2023

Abliva’s Drug Candidate NV354 Granted Orphan Drug Designation for the Treatment of Mitochondrial Disease

Abliva Nomination Committee to propose Edwin Moses as a new Board member and incoming Chair of the Board of Directors at upcoming General Meetings

Abliva Announces Issuance of a New U.S. Patent for Therapeutic Compound NV354

Abliva initiates the global FALCON study with lead candidate KL1333

Abliva to participate in World Mitochondrial Disease Week 2022

Abliva to issue the Q1 Interim Report by May 31st

Abliva’s IND for clinical development of KL1333 approved by FDA

Abliva to participate in World Mitochondrial Disease Week 2021

Abliva drug candidate NV354 to progress to clinical development following positive regulatory review

Abliva reports positive clinical Phase 1a/b results for KL1333 including signs of efficacy in PMD patients